Technology Insight: cytotoxic drug immunoconjugates for cancer therapy
Alejandro D Ricart and Anthony W Tolcher*
Correspondence *Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, Suite Z418, 7979 Wurzbach Road, San Antonio, TX 78229, USA
Email atolcher@idd.org
The successful introduction of genetically engineered human and chimeric immunoglobulin proteins has established monoclonal antibodies as a validated approach for treating malignancies. This review examines the optimal design of these agents, the lessons learned from clinical immunoconjugate development, and the promising agents in early preclinical and clinical development for the treatment of cancer.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.